Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24468883 | 0.79 | KDM4C (0.35) | EPHX1LMNAMMP8 | |
| SCHEMBL22861695 | 0.79 | KDM4C (0.35) | EPHX1LMNAMMP8 | |
| SCHEMBL20016520 | 0.79 | KDM4C (0.39) | MEN1CYP3A4KMT2AEPHX1LMNA | |
| SCHEMBL24764060 | 0.79 | KDM4C (0.35) | EPHX1LMNAMMP8 | |
| SCHEMBL25894503 | 0.79 | KDM4C (0.39) | MEN1CYP3A4KMT2AEPHX1LMNA | |
| SCHEMBL27106026 | 0.79 | KDM4C (0.39) | MEN1CYP3A4KMT2AEPHX1LMNA | |
| SCHEMBL23451083 | 0.79 | EPHX1 (0.38) | MEN1KMT2AEPHX1LMNAMMP8 | |
| SCHEMBL20123226 | 0.79 | EPHX1 (0.47) | EPHX1 | |
| SCHEMBL21393320 | 0.79 | EPHX1 (0.47) | EPHX1 | |
| SCHEMBL24488462 | 0.79 | TDP1 (0.33) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | CSNK1A1, CSNK1E, CSNK1G3 | MEN1 1541/4885CYP3A4 4811/4885ALOX15 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.